Study of Tazemetostat in combination with lenalidomide and rituximab compared to tazemetostat with placebo in participants with Relapsed/Refractory Follicular Lymphoma

The participants of this study will have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as ‘relapsed’ when the disease has come back after treatment and ‘refractory’ when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of

A study to assess efficacy and safety of oral tazemetostat in adult participants with relapsed/refractory follicular lymphoma that does not have an “EZH2 gain-of-function” genetic mutation

The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an “EZH2” genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections,